Journal article
Monospecific anti-Ro52/TRIM21 antibodies in a tri-nation cohort of 1574 systemic sclerosis subjects: evidence of an association with interstitial lung disease and worse survival.
Abstract
OBJECTIVES: Autoantibodies directed against Ro52/TRIM21 are common in systemic sclerosis (SSc) but their clinical significance remains uncertain. The aim of this study was to assess the clinical correlates and survival of subjects with monospecific anti-Ro52/TRIM21 antibodies, i.e. anti-Ro52/TRIM21 antibodies in the absence of other SSc-related antibodies.
METHODS: A tri-nation (Canada, Australia, USA) cohort of 1574 SSc subjects was formed, …
Authors
Wodkowski M; Hudson M; Proudman S; Walker J; Stevens W; Nikpour M; Assassi S; Mayes MD; Wang M; Baron M
Journal
Clinical and Experimental Rheumatology, Vol. 33, No. 4 Suppl 91, pp. s131–s135
Publication Date
2015
ISSN
0392-856X
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AdultAgedAntibodies, AntinuclearAntibody SpecificityAustraliaBiomarkersCanadaFemaleHumansKaplan-Meier EstimateLogistic ModelsLung Diseases, InterstitialMaleMiddle AgedMultivariate AnalysisOdds RatioPredictive Value of TestsPrognosisProportional Hazards ModelsRibonucleoproteinsRisk FactorsScleroderma, SystemicSerologic TestsTime FactorsUnited States